Country Updates

Track Global PrEP Use

For insights on the full scope of PrEP use around the world, AVAC’s database of programs delivering oral PrEP, planned, current and completed, offers detailed information, updated quarterly.

  • Data on PrEP users, by country
  • Programs delivering PrEP, including demonstration projects, national rollout programs and other initiatives
  • Funding sources
  • Country guidelines and program targets, where available
  • Drug registration status
  • And more!!

Download it here.

For a look at PrEP access nation-by-nation, the country pages (linked below) include updates from national governments and in-country partners.

We rely on information provided by implementing projects and other partners to keep our data current. There may be programs missing. Please let us know if there are other initiatives we should include!

Country Updates

Australia / Bahamas / Barbados / Belgium / Benin / Botswana / Brazil / Burkina Faso / Canada / China / Côte d'Ivoire / Croatia / Czech Republic / Democratic Republic of Congo / Denmark / Dominican Republic / Eritrea / Ethiopia / France / Georgia / Germany / Greece / Haiti / India / Ireland / Israel / Kenya / Italy / Japan / Laos / Lesotho / Malawi / Malaysia / Mali / Mexico / Morocco / Mozambique / Namibia / Netherlands / New Zealand / Nigeria / Norway / Peru / Philippines / Portugal / Senegal / Slovenia / South Africa / South Korea / Spain / Swaziland / Sweden / Switzerland / Taiwan / Tanzania / Thailand / Togo / Uganda / Ukraine / United Kingdom / United States / Vietnam / Zambia / Zimbabwe

*if your country is not listed and you would like it to be, please contact us here!

News Spotlight

  • FDA Approves Truvada as PrEP for Adolescents at Risk for HIV

    May 15, 2018

    The US Food and Drug Administration has expanded the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV to include adolescents. Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.

    Read more

  • Early PrEP Uptake in Africa Study Gives Support for Possibility of Wider Acceptance

    May 9, 2018

    New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP started taking the drug within 30 days — according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.

    Read more